PDB38 REAL-WORLD COMPARISON OF HOSPITALIZATION COSTS FOR HEART FAILURE IN T2DM PATIENTS WITH CARDIOVASCULAR DISEASE TREATED WITH CANAGLIFLOZIN VERSUS OTHER ANTIHYPERGLYCEMIC AGENTS